Loading...
Market
What will be AXS-05's market share in Alzheimer's treatment by end of 2026 if approved?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Market analysis reports from sources like Statista or Grand View Research
Story
Axsome Therapeutics Plans FDA NDA Submission for AXS-05 in Alzheimer’s Disease in 2H 2025 After Phase 3 Trials Show p=0.001
Dec 30, 2024, 12:40 PM
Axsome Therapeutics has announced plans to submit a New Drug Application (NDA) to the FDA for its Alzheimer’s disease treatment, AXS-05, in the second half of 2025. This decision follows the completion of a Phase 3 clinical program, which reportedly achieved its primary endpoint compared to placebo, with a p-value of 0.001 for time to relapse. However, the results from the ADVANCE-2 trial did not demonstrate statistical significance, although there were numerically greater improvements with AXS-05 over placebo in both primary and secondary endpoints. The mixed results from these trials have raised questions about the approvability of the data package by the FDA, but Axsome remains optimistic about moving forward.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Withdrawn by manufacturer • 25%
FDA approved and in market • 25%
Pending approval • 25%
Rejected by FDA • 25%
30% to 50% • 25%
10% to 30% • 25%
Less than 10% • 25%
More than 50% • 25%
Leqembi leads • 25%
Other treatments lead • 25%
Donanemab leads • 25%
Both have equal share • 25%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
No • 50%
Yes • 50%
Less than 10% • 25%
20-30% • 25%
More than 30% • 25%
10-20% • 25%
More than 5 new treatments • 25%
4-5 new treatments • 25%
2-3 new treatments • 25%
0-1 new treatments • 25%
No dominant company • 25%
Eli Lilly • 25%
Eisai and Biogen • 25%
Other companies • 25%
20% to 40% • 25%
More than 60% • 25%
Less than 20% • 25%
40% to 60% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%